Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Autor: S. R. Lentz, M. Cerqueira, D. Janic, C. Kempton, I. Matytsina, M. Misgav, J. Oldenburg, M. Ozelo, M. Recht, A. Rosholm, A. Savic, T. Suzuki, A. Tiede, E. Santagostino

Publikováno v: Haemophilia. 22:e445-e449

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::074fcb5d061bb214af08e10774ba5d5a
https://doi.org/10.1111/hae.12990

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Autor: A. Tiede, Paul Giangrande, K. Hampton, T. Lambert, Meera Chitlur, L. Alberio, C. Negrier, H. Takedani, Michael Recht, S. Lentz, Woei Tsay, S. Dunkley, Miguel A. Escobar, T. Fujii, P. Kampmann, Christine M. Knoll, M. Shima, T. A. Andreeva, Peter G. Jönsson, Steven R. Lentz, Chris Barnes, L. Nemes, Johannes Oldenburg, K. Fukutake, B. Brand, H. Hanabusa, Elena Santagostino, M. Guerrera, E. Cockrell, Tadashi Matsushita, Jerry S. Powell, Lone Hvitfeldt Poulsen, Ralph A. Gruppo, Laszlo Nemes, J. Morales, C. Rothschild, G. Thomson, P. Chowdary, J. Felgenhauer, S. Zupancic-Salek, J. Sathar, N. Apollonsky, A. Tosetto, Roshni Kulkarni, J. Lazarchick, E. M. Mingot, S. Madoiwa, M. Misgav, V Jiménez Yuste, Z. Boda, K. Meijer, E. Zetterberg, G. K. Guron, M. Castro Ozelo, G. R. Nagasubramanian, S. Kearney, Pratima Chowdary, J. Oldenburg, C. Albayrak, Frank W.G. Leebeek, Silke Ehrenforth, Savita Rangarajan, Tatiana Andreeva, K. Kavakli, H. Eichler, L. H. Poulsen, Faraizah Abdul Karim, A. Kutlar, J. Wright, M. Trossaert, P. Kavasch, M. C. Shen, Chur Woo You, P. A. Holme, E. Santagostino, Wan Hui Ong Clausen, N. Curry, I. Sasmaz, W. Miesbach, A. Shibuya, A. Paroskie-Wheeler, E. Lowe, Clifford M Takemoto, D. Yee, F. Boehlen, S. Brown, F. W. G. Leebeek, J. Lasky, Peter William Collins, T. Sato, Robert Klamroth, K. Dunsmore

Publikováno v: Thrombosis and Haemostasis, 117(2), 252-261. Georg Thieme Verlag
Giangrande, P, Andreeva, T, Chowdary, P, Ehrenforth, S, Hanabusa, H, Leebeek, F W G, Lentz, S R, Nemes, L, Poulsen, L H, Santagostino, E, You, C W, Clausen, W H O, Jönsson, P G, Oldenburg, J & Pathfinder™2 Investigators 2017, ' Clinical evaluation of glycoPEGylated recombinant FVIII : Efficacy and safety in severe haemophilia A ', Thrombosis and Haemostasis, pp. 252-261 . https://doi.org/10.1160/TH16-06-0444

Turoctocog alfa pegol (N8-GP) is a novel glycoPEGylated extended half-life recombinant factor VIII (FVIII) product developed for prophylaxis and treatment of bleeds in patients with haemophilia A, to enable higher activity levels with less frequent i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deca7c652b62e159aa11378000e7fe8c
https://pure.eur.nl/en/publications/5f120d71-685a-4410-9b98-59e6346a7976

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Recombinant activated factor VII (NovoSeventm): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding

Autor: Y. Kluger, D. Pauzner, R. Geenberg, J. Klausner, M. Misgav, A. Mayo, O. Ben-Tal

Publikováno v: Vox Sanguinis. 87:34-40

Background and Objectives Recombinant activated factor VII (rFVIIa, NovoSeven™) has been used off-label for various conditions. A protocol for its use in acute, uncontrolled life-threatening bleeding, was devised and employed. A haematologist/trans

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b95ee9cfa37fc99f83ff0a70529f632
https://doi.org/10.1111/j.1423-0410.2004.00533.x